A highly specific functional test for factor V Leiden: A modified tissue factor assay for activated protein C resistance

Haemostasis

Volumn 27, Issue 6, 1998, Pages 290-304

  Arkel, Y S ^a   Ku, D H ^a   Kamiyama, M ^a   Pajaro, R ^a   Alder, H ^b   Marchand, A ^a  

^a OVERLOOK HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

APC resistance; Factor V Leiden; Factor V ratio

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HEPARIN; PHOSPHOLIPID; SILICON DIOXIDE; THROMBOPLASTIN; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ACTIVATED PROTEIN C RESISTANCE; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION TESTS; FACTOR V; HUMANS; INDICATORS AND REAGENTS; KAOLIN; LUPUS COAGULATION INHIBITOR; MUTATION; PARTIAL THROMBOPLASTIN TIME; PHOSPHOLIPIDS; POLYMERASE CHAIN REACTION; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SILICON DIOXIDE; THROMBOPLASTIN;

EID: 3543142333     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Rosen S, Johansson K, Lindberg K, Dahlbäck B: Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994;72:255-260.
2. Stirling D, White A, Clarkson J, Stewart A, Ludlam CA: A comparison between functional and genetic testing for activated protein C resistance (APCR). Blood Coagul Fibrinolysis 1995;6:154.
3. de Ronde H, Bertina RM: Laboratory diagnosis of APCR resistance: A critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994;72: 880-886.
4. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Predication of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008.
5. Svensson PJ, Dahlbäck B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-522.
6. 506 allele. Thromb Haemost 1995;74:1380-1381.
7. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J: Modified test for activated protein C resistance. Lancet 1994;344:1162-1163.
8. Trossaert M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA: Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344:1709.
9. Tosetto A, Rodeghiero F: Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995;73:732-733.
10. Cadroy Y, Sie P, Alhenc-Geles M, Aiach M: Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Thromb Haemost 1995; 73:734-735.
11. Zoller B, Svensson PJ, He X, Dalhbäck B: Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94: 2521-2524.
12. Thiagaajan P, Pengo V, Shaoiro SS: The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986;68: 869-874.
13. Triplett DA, Brandt JT, Kaczor D, Schaeffer J: Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983;79:678-682.
14. Kirschbaum NE, Foster PA: The polymerase chain reaction with sequence-specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thromb Haemost 1995;74: 874-878.
15. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-79.
16. Rosendaal RF, Bertina RM, Reitsma PH: Evaluation of activated protein C resistance in stored plasma. Lancet 1994;343:1289-1290.
17. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342: 1503-1506.
18. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR: High prevalence of a mutation in the factor V gene within the UK population: Relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994;88:219-222.
19. Greengard JS, Sun X, Xu X, Fernandez JA, Griggin JH, Evatt B: Activated protein C resistance caused by Arg5060Gln mutation in factor Va. Lancet 1994;343:1361-1362.
20. Griffin J, Evatt B, Wideman C, Fernandez J: Anticoagulant protein C pathway defective in majority of thrombophilia patients. Blood 1993; 82:1989-1993.
21. Sun X, Evatt B, Griffin JH: Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994;83:3120-3125.
22. Halbmayer WM, Haushofer A, Schon R, Fischer M: The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994;5:51-57.
23. Halbmayer WM, Haushofer A, Schon R, Fisher M: Influence of lupus anticoagulant on a commercially available kit for APC resistance. Thromb Haemost 1994;72:645-646.
24. Marciniac E, Romond EH: Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 1989;74:2426-2432.
25. Malia RG, Kitchen S, Greaves M, Preston FE: Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990;76:101-107.
26. Bokarewa MI, Bremme K, Falk G, Stein-Linder M, Egberg N, Blomback M: Studies on phospholipid antibodies, APC resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995;78: 193-200.
27. Lee L, Baglin T: Platelet-phospholipid-dependent thrombin generation in thrombocytosis and thrombocytopenia. Br J Haematol 1995; 89:131-136.
28. Rosing J, Tans G, Grovers-Riemslag J, Zwaal R, Hemker H: The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980;255:274-283.
29. Girolami A, Simioni P, Scarano L: Evaluation of activated protein C resistance in stored plasma. Lancet 1993;343:1288-1289.
30. Shizuka H: False-positive activated protein C (APC) sensitivity ratio caused by freezing and by contamination of plasma with platelets. Thromb Res 1995;78:189-190.
31. Trossaert M, Conrad J, Horellou M, Samama M: Influence of storage conditions on activated protein C resistance assay. Thromb Haemost 1995;73:162-166.
32. 2-Glyoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996;75:49-55.
33. a in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995;85:1704-1711.